BA1302 GRANTED ODD FOR SQNSCLC AND PANCREATIC CANCER BY U.S. FDA

Boan Holds BPD Type 2b Meeting with FDA on BA1104

Boan Biotech announced that regarding its self-developed BA1104 (Nivolumab Injection), the company has held a Biological Product Development (BPD) type 2b meeting with the U.S. Food and Drug Administr...

NOTICE OF BOARD MEETING

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025

Phase 3 Trial Results of Boan Biotech’s BA1102 (Denosumab Injection) Published in Journal of Bone Oncology

The Phase 3 trial results of Boan Biotech’s anti-tumor denosumab injection (Chinese trade name: Boluojia, code-named BA1102, and formerly code-named LY01011) were recently published in Journal o...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025

FINANCE LEASE AGREEMENT

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024

Boan published a review of potential solid tumor target CD228

On December 15, 2024, a comprehensive review article written by Boan Biotech titled "Unlocking the potential of melanotransferrin (CD228): implications for targeted drug development and novel the...

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG